丹参川芎嗪对慢性阻塞性肺疾病急性加重期序贯机械通气患者呼吸功能的影响
|
摘要
目的探讨丹参川芎嗪对慢性阻塞性肺疾病急性加重期序贯机械通气患者呼吸功能的影响。方法选取2016年1月～2017年4月我院慢性阻塞性肺疾病急性加重期患者98例,按照随机数字表法分为两组。对照组行常规西医治疗,实验组在对照组治疗的基础上加用丹参川芎嗪治疗。比较两组患者血气指标、肺功能水平、免疫指标水平、机械通气时间、脱机率及不良反应率。结果实验组治疗后的PaO_2、SpO_2表达水平相比于治疗前均明显上升,PaCO_2水平较前下降,实验组指标改善情况较对照组佳,差异具有统计学意义(P<0.05);两组患者治疗后的FEV1、FEV1/FCV、PEF水平比治疗前均有上升,实验组指标改善情况较对照组佳,差异具有统计学意义(P<0.05);两组患者治疗后的总T淋巴细胞、NK细胞比治疗前均有上升,实验组指标改善情况较对照组佳,差异具有统计学意义(P<0.05);实验组有创机械通气时间及总机械通气时间比对照组短,差异具有统计学意义(P<0.05);实验组脱机成功率高于对照组,差异具有统计学意义(P<0.05)。结论丹参川芎嗪治疗慢性阻塞性肺疾病急性加重期序贯机械通气,能够明显调节患者血气指标、提高患者呼吸功能及免疫功能、减少机械通气时间、提高脱机率及降低用药后不良反应发生率。
Objective To investigate the effect of Danshen ligustrazine on respiratory function in sequential mechanical ventilation patients with acute exacerbation of chronic obstructive pulmonary disease. Methods 98 patients with acute exacerbation of chronic obstructive pulmonary disease in our hospital from January 2016 to April 2017 were enrolled and divided into two groups according to the random number table method. The control group was received routine Western medicine treatment, and the combined group was treated with Danshen ligustrazine based on the treatment of the control group. The blood gas index, lung function level, immune index level, duration of mechanical ventilation,successful rate of weaning and incidence of adverse reactions. Results The expression levels of PaO_2 and SpO_2 in the experimental group were significantly higher than those before treatment, and the level of PaCO_2 in the experimental group was lower than that in the control group. The improvement of indicators in the experimental group was better than that of the control group, and the difference was statistically significant(P<0.05). The levels of FEV1, FEV1/FCV and PEF after treatment in two groups were higher than those before treatment. The improvement of indicators in the experimental group was better than that of the control group, and the difference was statistically significant(P<0.05). The total T lymphocytes, The NK cells after treatment in the two groups increased compared with those before treatment. The improvement of the experimental group was better than that of the control group, and the difference was statistically significant(P<0.05). The invasive mechanical ventilation time and total mechanical ventilation time of the experimental group were shorter than those of the control group, and the difference was statistically significant(P<0.05). The success rate of taking off the ventilator and total mechanical ventilation time in the experimental group was higher than that of the control group, and the difference was statistically significant(P<0.05). Conclusion Danshen ligustrazine combined with sequential mechanical ventilation in the treatment of acute exacerbation of chronic obstructive pulmonary disease can significantly regulate blood gas parameters, improve respiratory function and immune function, reduce mechanical ventilation time, increase the success rate of taking off the ventilator and reduce the incidence of adverse reactions after medication.
Objective To investigate the effect of Danshen ligustrazine on respiratory function in sequential mechanical ventilation patients with acute exacerbation of chronic obstructive pulmonary disease. Methods 98 patients with acute exacerbation of chronic obstructive pulmonary disease in our hospital from January 2016 to April 2017 were enrolled and divided into two groups according to the random number table method. The control group was received routine Western medicine treatment, and the combined group was treated with Danshen ligustrazine based on the treatment of the control group. The blood gas index, lung function level, immune index level, duration of mechanical ventilation,successful rate of weaning and incidence of adverse reactions. Results The expression levels of PaO_2 and SpO_2 in the experimental group were significantly higher than those before treatment, and the level of PaCO_2 in the experimental group was lower than that in the control group. The improvement of indicators in the experimental group was better than that of the control group, and the difference was statistically significant(P<0.05). The levels of FEV1, FEV1/FCV and PEF after treatment in two groups were higher than those before treatment. The improvement of indicators in the experimental group was better than that of the control group, and the difference was statistically significant(P<0.05). The total T lymphocytes, The NK cells after treatment in the two groups increased compared with those before treatment. The improvement of the experimental group was better than that of the control group, and the difference was statistically significant(P<0.05). The invasive mechanical ventilation time and total mechanical ventilation time of the experimental group were shorter than those of the control group, and the difference was statistically significant(P<0.05). The success rate of taking off the ventilator and total mechanical ventilation time in the experimental group was higher than that of the control group, and the difference was statistically significant(P<0.05). Conclusion Danshen ligustrazine combined with sequential mechanical ventilation in the treatment of acute exacerbation of chronic obstructive pulmonary disease can significantly regulate blood gas parameters, improve respiratory function and immune function, reduce mechanical ventilation time, increase the success rate of taking off the ventilator and reduce the incidence of adverse reactions after medication.
引文
[1]王至婉,李建生,陈楚湘,等.基于贝叶斯网络构建慢性阻塞性肺疾病急性加重期痰热壅肺证症状与证候间关联模式[J].中医杂志,2018,59(3):203-206.
[2]胡克增,陈汉才,陈辉,等.阿奇霉素联合头孢类药物在慢性阻塞性肺疾病急性加重期抗感染治疗中的疗效[J].中华医院感染学杂志,2018,28(3):360-363.
[3]张林,范晓东,许红阳.乙酰半胱氨酸对慢性阻塞性肺疾病急性加重期患者肺功能和血清炎性因子及抗氧化指标水平的影响[J].中国医药,2018,13(7):1016-1020.
[4]佘小银,穆菊香.序贯通气在慢性阻塞性肺疾病合并呼吸衰竭患者撤机中的应用[J].内科急危重症杂志,2014,20(6):401-402.
[5]贾珺.无创正压通气在慢性阻塞性肺疾病呼吸衰竭合并心力衰竭中的作用[J].中西医结合心脑血管病杂志,2017,15(6):758-760.
[6]陈杰.经鼻无创同步间歇指令通气在慢性阻塞性肺疾病急性加重期合并呼吸衰竭治疗中的应用效果[J].中国医药,2017,12(7):1008-1011.
[7]冯云霞,侯佳倩.丹参川芎嗪联合综合干预对慢性阻塞性肺疾病急性加重期合并呼吸衰竭患者炎性反应及肺功能的影响[J].吉林中医药,2018,38(1):41-44.
[8]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,6(4):67-80.
[9]刘云芳,包宁,杨孝芳.集束化无创机械通气治疗慢性阻塞性肺疾病急性加重期合并HE患者的临床效果研究[J].中国医学装备,2018,15(4):53-56.
[10]吴成明,程玉峰,赵园园.桑白皮汤对慢性阻塞性肺疾病急性加重期(痰热郁肺证)患者氧化应激的影响[J]中国中医急症,2018,27(2):331-333.
[11]陶凌,程克文,洪雁,等.111例慢性阻塞性肺疾病急性加重期合并心律失常病因分析[J].临床肺科杂志,2016,21(9):1621-1623.
[12]潘小丹,范良,卢保强,等.加味小青龙汤合膀胱经姜疗治疗外寒内饮型慢性阻塞性肺疾病急性加重期临床研究[J].中国中医药信息杂志,2018,25(3):34-37.
[13]甘文云,王腾,李海明,等.丹参川芎嗪治疗慢性阻塞性肺疾病急性加重期并肺源性心脏病的临床观察[J]中国临床医学,2015,22(2):189-191.
[14]孟素秋,袁继印,杨文宝,等.低分子肝素配合双水平无创正压通气对COPD合并Ⅱ型呼吸衰竭患者肺功能及氧代谢的影响[J].中国医师杂志,2017,19(4):614-616.
[15]曾源,林雪妹,邓可波,等.痰热清注射液联合丹参川芎嗪注射液治疗慢性阻塞性肺疾病急性加重期临床研究[J].国际中医中药杂志,2018,40(4):296-299.
[16]袁泉,罗雪飞,邓治平,等.丹参川芎嗪对慢性阻塞性肺疾病急性加重期肺动脉高压的影响[J].实用医院临床杂志,2017,14(5):174-176.
[17]贾铷,陈运转,祝伟.丹参川芎嗪对慢性阻塞性肺疾病合并呼吸衰竭患者肺功能、炎性反应因子的变化[J].世界中医药,2017,12(6):1361-1363.
[18]杨多华,宋德香,奚晴超,等.疏风解毒胶囊联合丹参川芎嗪注射液治疗慢性阻塞性肺疾病急性加重期的临床研究[J].现代药物与临床,2017,32(7):1264-1268.
[19]王彬,罗毅,梁桂林,等.痰热清注射液联合丹参川芎嗪治疗慢性阻塞性肺疾病的疗效评价及作用机制[J]广东医学,2016,37(6):921-924.
[20]郑玉兰,付文荣,曹锋生.丹参川芎嗪对慢性阻塞性肺疾病急性加重合并呼吸衰竭患者肺功能及炎症因子的影响[J].中国老年学杂志,2015,25(24):7109-7111.
[2]胡克增,陈汉才,陈辉,等.阿奇霉素联合头孢类药物在慢性阻塞性肺疾病急性加重期抗感染治疗中的疗效[J].中华医院感染学杂志,2018,28(3):360-363.
[3]张林,范晓东,许红阳.乙酰半胱氨酸对慢性阻塞性肺疾病急性加重期患者肺功能和血清炎性因子及抗氧化指标水平的影响[J].中国医药,2018,13(7):1016-1020.
[4]佘小银,穆菊香.序贯通气在慢性阻塞性肺疾病合并呼吸衰竭患者撤机中的应用[J].内科急危重症杂志,2014,20(6):401-402.
[5]贾珺.无创正压通气在慢性阻塞性肺疾病呼吸衰竭合并心力衰竭中的作用[J].中西医结合心脑血管病杂志,2017,15(6):758-760.
[6]陈杰.经鼻无创同步间歇指令通气在慢性阻塞性肺疾病急性加重期合并呼吸衰竭治疗中的应用效果[J].中国医药,2017,12(7):1008-1011.
[7]冯云霞,侯佳倩.丹参川芎嗪联合综合干预对慢性阻塞性肺疾病急性加重期合并呼吸衰竭患者炎性反应及肺功能的影响[J].吉林中医药,2018,38(1):41-44.
[8]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志,2013,6(4):67-80.
[9]刘云芳,包宁,杨孝芳.集束化无创机械通气治疗慢性阻塞性肺疾病急性加重期合并HE患者的临床效果研究[J].中国医学装备,2018,15(4):53-56.
[10]吴成明,程玉峰,赵园园.桑白皮汤对慢性阻塞性肺疾病急性加重期(痰热郁肺证)患者氧化应激的影响[J]中国中医急症,2018,27(2):331-333.
[11]陶凌,程克文,洪雁,等.111例慢性阻塞性肺疾病急性加重期合并心律失常病因分析[J].临床肺科杂志,2016,21(9):1621-1623.
[12]潘小丹,范良,卢保强,等.加味小青龙汤合膀胱经姜疗治疗外寒内饮型慢性阻塞性肺疾病急性加重期临床研究[J].中国中医药信息杂志,2018,25(3):34-37.
[13]甘文云,王腾,李海明,等.丹参川芎嗪治疗慢性阻塞性肺疾病急性加重期并肺源性心脏病的临床观察[J]中国临床医学,2015,22(2):189-191.
[14]孟素秋,袁继印,杨文宝,等.低分子肝素配合双水平无创正压通气对COPD合并Ⅱ型呼吸衰竭患者肺功能及氧代谢的影响[J].中国医师杂志,2017,19(4):614-616.
[15]曾源,林雪妹,邓可波,等.痰热清注射液联合丹参川芎嗪注射液治疗慢性阻塞性肺疾病急性加重期临床研究[J].国际中医中药杂志,2018,40(4):296-299.
[16]袁泉,罗雪飞,邓治平,等.丹参川芎嗪对慢性阻塞性肺疾病急性加重期肺动脉高压的影响[J].实用医院临床杂志,2017,14(5):174-176.
[17]贾铷,陈运转,祝伟.丹参川芎嗪对慢性阻塞性肺疾病合并呼吸衰竭患者肺功能、炎性反应因子的变化[J].世界中医药,2017,12(6):1361-1363.
[18]杨多华,宋德香,奚晴超,等.疏风解毒胶囊联合丹参川芎嗪注射液治疗慢性阻塞性肺疾病急性加重期的临床研究[J].现代药物与临床,2017,32(7):1264-1268.
[19]王彬,罗毅,梁桂林,等.痰热清注射液联合丹参川芎嗪治疗慢性阻塞性肺疾病的疗效评价及作用机制[J]广东医学,2016,37(6):921-924.
[20]郑玉兰,付文荣,曹锋生.丹参川芎嗪对慢性阻塞性肺疾病急性加重合并呼吸衰竭患者肺功能及炎症因子的影响[J].中国老年学杂志,2015,25(24):7109-7111.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |